ArticleActa neuropathologica2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Abstract readLetter
In one paragraph
Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Case Report: The revelation of a new pathogenic variant in the POT1 gene in a patient with a pediatric high-grade glioma and a renal cell carcinoma.Frontiers in oncology · 2026Article
- Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patients.Journal of clinical pathology · 2025Article
- Identification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis.European journal of medical research · 2025Article
- Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review.Cancers · 2024Review
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant-type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma.Brain pathology (Zurich, Switzerland) · 2023Article
- RNA fusion transcript panel identifies diverse repertoire of fusions in adult glioma patients with therapeutic implications.Neuro-oncology practice · 2023Article
- Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas.Genes · 2023Review
- Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.Brain tumor pathology · 2023Review
- Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature.NPJ precision oncology · 2023Article
- NTRK-rearranged spindle cell neoplasms are ubiquitous tumours of myofibroblastic lineage with a distinct methylation class.Histopathology · 2023Article
- Glioblastoma: Current Status, Emerging Targets, and Recent Advances.Journal of medicinal chemistry · 2022Review
- Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.Brain pathology (Zurich, Switzerland) · 2022Review
- Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.Neuro-oncology · 2022Article
- Prognostic Role of M6A-Associated Immune Genes and Cluster-Related Tumor Microenvironment Analysis: A Multi-Omics Practice in Stomach Adenocarcinoma.Frontiers in cell and developmental biology · 2022Article
- Detection ofFrontiers in cell and developmental biology · 2022Article
- Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring aNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Philipp Sievers *Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0003-3237-6021
Damian Stichel *Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Martin SillHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Daniel SchrimpfDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Dominik SturmHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Florian SeltHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Jonas EckerHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Daniel KazdalInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Evelina MieleDepartment of Pediatric Onco-Hematology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Mariëtte E G KranendonkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Bastiaan B J TopsPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Patricia Kohlhof-MeineckeDepartment of Pathology, Klinikum Stuttgart, Stuttgart, Germany.
Rudi BeschornerDepartment of Neuropathology, University of Tübingen, Tübingen, Germany.
Christof M KrammDivision of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.
Martin HasselblattInstitute of Neuropathology, University Hospital Münster, Münster, Germany.
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
David CapperCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Neuropathology, Berlin, Germany.
Pieter WesselingPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Andrey KorshunovDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Stefan M PfisterHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Wolfgang WickClinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Felix SahmDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. felix.sahm@med.uni-heidelberg.de.ORCID 0000-0001-5441-1962
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adaptor Proteins, Signal TransducingBrain NeoplasmsGliomaGolgi Matrix ProteinsHumansMolecular Targeted TherapyOncogene FusionOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsAdaptor Proteins, Signal TransducingGolgi Matrix ProteinsGOPC protein, humanOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.